MDxHealth SA (MDXH)

NCM – Real Time Price. Currency in USD

1.87

-0.12 (-6.03%)

At close: May 12, 2026, 4:00 PM EDT

1.90

+0.03 (1.60%)

After-hours: May 12, 2026, 5:52 PM EDT

16.03.2026

Mdxhealth Highlights Data from Oxford's ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026

27.02.2026

MDxHealth SA (MDXH) Q4 2025 Earnings Call Transcript

12.02.2026

Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26

Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26 Company to Host Conference Call with Live Q&A, February 26, 2026, at 4:30pm ET / 22:30 CET IRVINE, California – February 12, 2026 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the fourth quarter and full year ended December 31, 2025, after market close on Thursday, February 26, 2026. Title: Mdxhealth Presents Fourth Quarter and Full Year 2025 Financial Results andCorporate Update Conference Call and Webcast Date: February 26, 2026 Time: 4:30pm ET/ 22:30 CET Conference Call D ial-in Details: United States: 1-844-825-9789 Int'l: 1-412-317-5180 Belgium: 0800 38 961 United Kingdom: 0800 279 9489 Conference ID: 10206764 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1753070&tp_key=27bce7d4de The webcast should be accessed 15 minutes prior to the conference call start time.

12.01.2026

MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences

06.01.2026

Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer

13.11.2025

MDxHealth SA (MDXH) Q3 2025 Earnings Call Transcript

MDxHealth SA ( MDXH ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Michael McGarrity - CEO & Executive Director Scott McMahan - Vice President of Finance and Accounting Conference Call Participants John Fraunces - Lifesci Advisors, LLC Daniel Brennan - TD Cowen, Research Division Andrew Brackmann - William Blair & Company L.L.C., Research Division William Bonello - Craig-Hallum Capital Group LLC, Research Division Mark Massaro - BTIG, LLC, Research Division Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to the MDxHealth Third Quarter 2025 Earnings Conference Call.

29.10.2025

Here's Why Momentum in MDxHealth SA (MDXH) Should Keep going

If you are looking for stocks that are well positioned to maintain their recent uptrend, MDxHealth SA (MDXH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Videos

No Data

There is no data to display

Press releases

16.03.2026

Mdxhealth Highlights Data from Oxford's ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026

12.01.2026

MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences

06.01.2026

Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer

05.08.2025

Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne

M dxh ealth Reports Preliminary Second Quarter 202 5 Results , Reaches Positive Adjusted EBITDA , and A nnounces Acquisition of Exo some D iagnostics B usiness from Bio - Techne

MDxHealth SA (MDXH)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

MDxHealth SA (MDXH)

Mdxhealth Highlights Data from Oxford's ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026

MDxHealth SA (MDXH) Q4 2025 Earnings Call Transcript

Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26

MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences

Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer

MDxHealth SA (MDXH) Q3 2025 Earnings Call Transcript

Here's Why Momentum in MDxHealth SA (MDXH) Should Keep going

Videos

No Data

Press releases

Mdxhealth Highlights Data from Oxford's ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026

MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences

Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer

Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne

Mdxhealth Highlights Data from Oxford's ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026

MDxHealth SA (MDXH) Q4 2025 Earnings Call Transcript

Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26

MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences

Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer

MDxHealth SA (MDXH) Q3 2025 Earnings Call Transcript

Here's Why Momentum in MDxHealth SA (MDXH) Should Keep going

Videos

No Data

Press releases

Mdxhealth Highlights Data from Oxford's ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026

MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences

Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer

Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne

Search stocks

MDxHealth SA (MDXH)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

MDxHealth SA (MDXH)

Mdxhealth Highlights Data from Oxford's ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026

MDxHealth SA (MDXH) Q4 2025 Earnings Call Transcript

Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26

MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences

Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer

MDxHealth SA (MDXH) Q3 2025 Earnings Call Transcript

Here's Why Momentum in MDxHealth SA (MDXH) Should Keep going

Videos

No Data

Press releases

Mdxhealth Highlights Data from Oxford's ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026

MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences

Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer

Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne

Mdxhealth Highlights Data from Oxford's ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026

MDxHealth SA (MDXH) Q4 2025 Earnings Call Transcript

Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26

MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences

Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer

MDxHealth SA (MDXH) Q3 2025 Earnings Call Transcript

Here's Why Momentum in MDxHealth SA (MDXH) Should Keep going

Videos

No Data

Press releases

Mdxhealth Highlights Data from Oxford's ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026

MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences

Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer

Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne